Details in Premium Report: 2020: 2019: 2018: 2017: 1-Year Growth Rate: 3-Year Growth Rate (CAGR): Note: Eisai Corporation of North America & Its Subsidiaries's revenues are gauged from an analysis of company filings. Ratio of basic salary and remuneration of women to men. Read our factsheet. In order to realize Eisai's purpose the human health care (hhc) concept, it is necessary to implement corporate policies based on a long-term perspective under a well-cultivated governance structure.We acknowledge that it is extremely important for our company to contribute to the sustainability of society by actively addressing global environmental and social issues. These data will be among nine abstracts shared in six oral and three . Eisai Laboratorios, S. de R. L. de C.V., located in Mexico, is a subsidiary of Eisai Inc. a company based in the United States. Published. The corporate landscape is changing and Integrated Reporting is an ideal tool with which to explore value creation. Copyright Eisai Co., Ltd. All Rights Reserved. adding the facilities should be integrated with hospitals and a healthcare staffing strategy prepared. Eisai Mexico has submitted for regulatory review several drug products to COFEPRIS (Federal Commission for the Protection against Sanitary Risks), while further developing its commercial operation for the introduction . Eisai Global. Diversity of governance bodies and employees. Senior Manager, Marketing IT Solutions. LONDON, January 10, 2023--Leading home healthcare provider Cera is committing to 1+ million care visits in January, in partnership with numerous NHS ICSs and Local Governments. An integrated report is a narrative document - in contrast to numerical financial statements - that explains how a company's current operations may affect its long-term profits. London, England, United Kingdom. Annual Report 2020(PDF) [3.7MB] Mission Statement (PDF) [417KB] Consolidated Financial Highlights (PDF) [462KB] Letter from the CEO. By using this site, you agree to our use of cookies. Eisai (OTCPK:ESALF): Q1 GAAP EPS of 85.20.Revenue of 165.58B (+7.5% Y/Y)Press Release FYCOMPA FOR ADJUNCTIVE TREATMENT OF PARTIAL ONSET SEIZURES LAUNCHED IN CHINA. The 2020 Integrated Report continues the new digital and fully interactive format created in 2018. GRI 405: Diversity and Equal Opportunity 2016. 2019. efforts go directly to the questions of whether and . In its 10th year, the Drugs to Watch report provides in-depth predictive analysis of drugs with the potential to transform treatment paradigms and serve unmet patient needs. Sustainable Access and Pricing Transparency Report. Integrated Reportsformerly Annual Reports 2020. (1) The Company's Corporate Philosophy is to give first thought to patients and their families, and increase the benefits that health care provides them. Welcome to Eisai, India. This direction of travel - which is voluntary - is focused on driving more authentic, comprehensive and meaningful information about all aspects of an organisation's performance and value creation story delivering benefits for both internal and external stakeholders. Letter from the CEO. Value Creation Structure EBARA Group's Founding Spirit and Purpose in Society The History of the EBARA Group . Read the CEO Letter; By: Ronak Patel . E-commerce and M-commerce platform. The targets are that by 2030, 80% of people living with diabetes mellitus are diagnosed, and that 80% . January 7, 2023. 2020 was a year none of us will ever forget. Eisai's commitment to healthcare began in Japan in 1941. Take a closer look at the many ways we've made pharmaceutical history. Integrated Report 2020 PDF | 18,434 KB. Stand alone document; Differentiation Level This COP qualifies for the Global Compact Active level 2020-2022 California Integrated Report (Clean Water Act Section 303(d) List and 305(b) Report) For the 2020-2022 Integrated Report, the Central Coast, Central Valley, and San Diego Regional Water Boards were "on cycle." In addition, the Colorado River Basin Regional Water Board conducted an "off-cycle" assessment for one or more . manufacturing of Drug Substances (Active Pharmaceutical Ingredients-APIs), FYE 3/2018 Earnings Release Presentation; Q&A; FYE 3/2018 2Q Earnings Release Presentation; Q&A; Business Strategy Conference. . 2021 U.S. This website uses cookies to enhance your browsing experience. Eisai Co., Ltd. It was listed on the Tokyo/Osaka stock exchange in 1961 and began its global operations soon after. Our water consumption also dropped by 38%. How Eisai is utilizing digital workspace innovations in a post-pandemic era. April 2019 - March 2020 Files. Eisai revenue for the twelve months ending June 30, 2022 was $4.769B, a 11.07% decline year-over-year. Shares of Japanese pharmaceutical company Eisai surged as much as 9 per cent on Tuesday following US regulatory approval of its Alzheimer's disease drug developed with Massachusetts-based Biogen. FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 Archive. Engineer with experience in design, quality assurance, and regulatory affairs of medical devices with an emphasis on the safe and secure end-user experience. LAUNCH OF ANTICANCER AGENT HALAVEN IN CHINA. SDG 1: End poverty in all its forms everywhere, SDG 2: End hunger, achieve food security and improved nutrition and promote sustainable agriculture, SDG 3: Ensure healthy lives and promote well-being for all at all ages, SDG 4: Ensure inclusive and equitable quality education and promote lifelong learning opportunities for all, SDG 5: Achieve gender equality and empower all women and girls, SDG 6: Ensure availability and sustainable management of water and sanitation for all, SDG 7: Ensure access to affordable, reliable, sustainable and modern energy for all, SDG 8: Promote sustained, inclusive and sustainable economic growth, full and productive employment and decent work for all, SDG 9: Build resilient infrastructure, promote inclusive and sustainable industrialization and foster innovation, SDG 10: Reduce inequality within and among countries, SDG 11: Make cities and human settlements inclusive, safe, resilient and sustainable, SDG 12: Ensure sustainable consumption and production patterns, SDG 13: Take urgent action to combat climate change and its impacts, SDG 14: Conserve and sustainably use the oceans, seas and marine resources for sustainable development, SDG 15: Protect, restore and promote sustainable use of terrestrial ecosystems, sustainably manage forests, combat desertification, and halt and reverse land degradation and halt biodiversity loss, SDG 16: Promote peaceful and inclusive societies for sustainable development, provide access to justice for all and build effective, accountable and inclusive institutions at all levels, SDG 17: Strengthen the means of implementation and revitalize the global partnership for sustainable development, Opportunities and responsibilities that one or more SDGs represent to our business, Where the companys priorities lie with respect to one or more SDGs, Goals and indicators set by our company with respect to one or more SDGs, How one or more SDGs are integrated into the companys business model, The (expected) outcomes and impact of your companys activities related to the SDGs, If the companies' activities related totheSDGs are undertaken in collaboration with other stakeholders, Other established or emerging best practices. Copyright Eisai Co., Ltd. All Rights Reserved. Eisai contributes to the sustainability of society through ESG (Environmental, Social, Governance) initiatives. EISAI COMPLETES CONSTRUCTION OF THE 5TH MANUFACTURING BUILDING AT KAWASHIMA INDUSTRIAL PARK IN JAPANTO STRENGTHEN ITS IN-HOUSE PRODUCTION FUNCTION FOR FORMULATING ANTI-CANCER AGENT LENVIMA, LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Demonstrated Statistically Significant Improvement in Overall Survival, Progression-Free Survival and Objective Response Rate Versus Chemotherapy in Patients With Advanced Endometrial Cancer Following Prior Systemic Therapy in Phase 3 StudyFirst Overall Survival Analysis for LENVIMA Plus KEYTRUDA Combination in a Phase 3 Study in Advanced Endometrial Cancer, BIOGEN FILES NEW DRUG APPLICATION FOR ADUCANUMAB IN JAPANIf approved, aducanumab would become the first treatment to meaningfully change the course of Alzheimers diseaseAducanumab is now under regulatory review in Japan, Europe and the United States, EISAI TO PRESENT ABSTRACTS ON ONCOLOGY PRODUCTS AND PIPELINE AT 43RD ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM, EISAI AND WREN THERAPEUTICS ENTER INTO RESEARCH COLLABORATION AGREEMENT FOR DRUG DISCOVERY FOR SYNUCLEINOPATHIESThis collaboration aims to develop a disease modifying treatment for synucleinopathies based on network kinetics of-synuclein misfolding and aggregation, EISAI TO PRESENT LATEST DATA ON PERAMPANEL AT THE 74TH AMERICAN EPILEPSY SOCIETY ANNUAL MEETING, AbbVie and Eisai Announce an approval for additional indication of HUMIRA, a fully Human Anti-TNF Monoclonal Antibody, for the treatment of pyoderma gangrenosum for the first time in the world, EISAI COMMENCES PaDiCo SMARTPHONE APPLICATION SERVICE IN JAPAN TO SUPPORT THE DAILY LIVES OF PATIENTS WITH PARKINSONS DISEASEWITH SIMPLE OPERATION, APP RECORDS AND VISUALIZES SYMPTOMS TO SUPPORT COMMUNICATION BETWEEN PATIENTS AND DOCTORS, EISAI SELECTED FOR MEMBERSHIP IN DOW JONES SUSTAINABILITY ASIA PACIFIC INDEX 2020 FOR SEVENTH TIME, JYSELECA (FILGOTINIB) FOR RHEUMATOID ARTHRITIS LAUNCHES IN JAPANA once-daily, oral, JAK inhibitor for the treatment of rheumatoid arthritis in patients who have had an inadequate response to conventional therapies, EISAI RECEIVES APPROVAL FOR INDICATION EXPANSION OF ANTI-EPILEPTIC AGENT FYCOMPA FOR USE IN PEDIATRIC PATIENTS, LENVIMA Plus KEYTRUDA Demonstrated Statistically Significant Improvement in Progression-Free Survival, Overall Survival and Objective Response Rate Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell CarcinomaLENVIMA Plus Everolimus Also Showed Statistically Significant Improvement in PFS and ORR Endpoints Versus SunitinibResults of Investigational Phase 3 CLEAR Trial (Study 307)/KEYNOTE-581 to be Presented at Upcoming Medical Meeting, Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimers Disease Using BloodThe Content Presented at the 13th Clinical Trials on Alzheimers Disease (CTAD) Conference, Update on FDA Advisory Committees meeting on aducanumab in Alzheimers disease, European Medicines Agency Accepts Biogens Aducanumab Marketing Authorization Application for Alzheimer's DiseaseIf approved, aducanumab would become the first therapy to reduce the clinical decline of Alzheimers disease and to meaningfully change the course of Alzheimers disease, EISAI TO PRESENT LATEST DATA ON PIPELINE ASSETS IN THE AREA OF ALZHEIMERS DISEASE AND DEMENTIA AT THE 13TH CLINICAL TRIALS ON ALZHEIMERS DISEASE CONFERENCE, EISAI AND JD HEALTH ESTABLISH A JOINT VENTURE COMPANY IN CHINA TO IMPLEMENT HEALTH SERVICE PLATFORMAiming to make a new contribution through a One-Stop Online Service for people living with Dementia in China, GLOBAL COALITION FOR ADAPTIVE RESEARCH, AMGEN, AND EISAI ANNOUNCE FIRST PATIENT ENROLLED IN INTERNATIONAL COVID-19 TRIALAMGEN AND EISAI TO PARTICIPATE IN THE IMMUNE MODULATION DOMAIN OF REMAP-COVID, AN ADAPTIVE CLINICAL TRIAL TO TEST INTERVENTIONS FOR PATIENTS HOSPITALIZED WITH COVID-19AMGENS APREMILAST AND EISAIS ERITORAN TO BE EVALUATED ACROSS MULTIPLE INTERNATIONAL TRIAL SITES WITHIN THE REMAP NETWORK, Eisai and Cogstate Expand Agreement for Global Development and Commercialization of Digital Cognitive Assessment Technologies, NOTICE REGARDING BIOGENS DISCLOSURE ABOUT THE SUBMISSION OF MARKETING AUTHORIZATION APPLICATION TO EUROPEAN MEDICINES AGENCY FOR ADUCANUMAB FOR ALZHEIMERS DISEASE, SUPPLEMENTARY NEW DRUG APPLICATIONS FOR ANTI-EPILEPTIC DRUG FYCOMPA AS MONOTHERAPY FOR PARTIAL-ONSET SEIZURES, PEDIATRIC INDICATION FOR PARTIAL-ONSET SEIZURES ACCEPTED IN CHINA, THE UNIVERSITY OF TOKYO AND EISAI ANNOUNCE RESEARCH COLLABORATION FOR THE DEVELOPMENT AND DRUG DISCOVERY OF TARGETED PROTEIN DEGRADATION TECHNOLOGYEstablishment of Social Cooperation Program Protein Degradation Drug Discovery, INDUSTRY-ACADEMIA-GOVERNMENT JOINT DEVELOPMENT AGREEMENT AIMING FOR DRUG DISCOVERY FOR COVID-19 UTILIZING ERITORAN AND E6011 CONCLUDED, NON-CLINICAL RESEARCH ACTIVITIES COMMENCEAdopted for the public call for AMED "Development of therapeutic drugs for the novel coronavirus infection (COVID-19)", Eisai and Seikagaku Enter into Agreement for the Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in South Korea, JYSELECA (FILGOTINIB) APPROVED IN JAPAN FOR RHEUMATOID ARTHRITISFilgotinib Demonstrates Durable Efficacy and Consistent Safety Profile Through 52 Weeks in Clinical Trials, EISAI RECEIVES POSITIVE OPINION FROM EMAS CHMP ON USE OF ANTIEPILEPTIC AGENT FYCOMPA IN PEDIATRIC PATIENTS, Eisai and Merck Present First-Time Data From Two Studies Evaluating KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020New Results Include Findings From the Phase 2 LEAP-004 Trial Showing an ORR of 21.4% in Patients With Unresectable or Advanced Melanoma Who Had Previously Progressed on an Anti-PD-1/PD-L1 Therapy, EISAI PRESENTS LATEST DATA OF PHASE I CLINICAL TRIAL ON LIPOSOMAL FORMULATION OF ANTI-CANCER AGENT HALAVEN (ERIBULIN) AT ESMO VIRTUAL CONGRESS 2020, EISAI ESTABLISHES PHARMA SALES SUBSIDIARY IN VIETNAM, EISAI TO PRESENT ABSTRACTS ON ONCOLOGY PRODUCTS AND PIPELINE AT ESMO VIRTUAL CONGRESS 2020, EISAI TO TAKE OVER MANUFACTURING AND MARKETING APPROVAL FOR EQUFINA 50MG TABLETS (SAFINAMIDE MESILATE) IN JAPAN FROM MEIJI SEIKA PHARMA, Relieving discomfort caused by dry skin with the moisturizing effect of pharmaceutical care productsEISAI TO LAUNCH SAHNE MEDICAL SPRAY AND SAHNE MEDICAL CREAMSahne Medical Spray is the first OTC drug spray-type lotion containing Heparinoid, EISAI TO PRESENT LATEST DATA OF LEMBOREXANT AT 34th ANNUAL SLEEP MEETING (SLEEP2020), FDA Accepts Biogens Aducanumab Biologics License Application for Alzheimer's Disease with Priority ReviewPriority Review accelerates FDA review time, with a Prescription Drug User Fee Act (PDUFA) target action on March 7, 2021If approved, aducanumab would be the first treatment to meaningfully change the course of Alzheimers disease, EISAI SUPPORTS RELIEF EFFORTS FOR THE HEAVY RAIN EVENT OF JULY 2020 IN JAPAN, APPLICATION FOR ADDITIONAL INDICATION OF ANTI CANCER AGENT LENVIMA FOR UNRESECTABLE THYMIC CARCINOMA SUBMITTED IN JAPAN, EISAI AND DeNA TO PROVIDE SMARTPHONE APP EASIIT APP THROUGH BUSINESS ALLIANCE AGREEMENTEISAI DEMENTIA PLATFORM EASIIT COMMENCES, EISAI LISTED FOR 19TH CONSECUTIVE YEAR IN FTSE4GOOD INDEX SERIES, AN INDEX FOR SOCIALLY RESPONSIBLE INVESTMENT, EISAI TO PRESENT LATEST DATA ON PIPELINE ASSETS IN THE AREA OF ALZHEIMERS DISEASE AND DEMENTIA AT THE ALZHEIMERS ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2020, Smartphone app for vital signs measurement of patients with the novel coronavirus infection Experimental study project adopted as AMED projectPreventing medical infrastructure collapse by a monitoring system linked to LINE, INITIATION OF NEW PHASE III CLINICAL STUDY (AHEAD 3-45) OF BAN2401 PRECLINICAL (ASYMPTOMATIC) ALZHEIMERS DISEASE, INDUSTRY-ACADEMIA-GOVERNMENT JOINT DEVELOPMENT AGREEMENT AIMING FOR DRUG DISCOVERY FOR SYSTEMIC LUPUS ERYTHEMATOSUS BY PRACTICAL APPLICATION OF TOLL-LIKE RECEPTOR RESEARCH CONCLUDEDRESEARCH ACTIVITIES COMMENCE, Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimers DiseaseIf approved, aducanumab would be the first treatment with the potential to meaningfully change the course of Alzheimers disease, Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma, EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION IN JAPAN FOR ANTICANCER AGENT TAZEMETOSTAT FOR EZH2 GENE MUTATION-POSITIVE FOLLICULAR LYMPHOMA, NEW DRUG APPLICATION FOR IN-HOUSE DEVELOPED NEW ANTI-INSOMNIA DRUG DAYVIGO ACCEPTED IN HONG KONGFIRST NEW DRUG APPLICATION FOR DAYVIGO IN ASIA OUTSIDE JAPAN, EISAI TO LAUNCH IN-HOUSE DEVELOPED NEW ANTI-INSOMNIA DRUG DAYVIGO (LEMBOREXANT) WITH INDICATION FOR INSOMNIA IN JAPAN, NEW FINE GRANULE FORMULATION OF ANTI-EPILEPTIC DRUG FYCOMPA LAUNCHED IN JAPAN, REMAP-CAP TO PARTNER WITH EISAI ON INNOVATIVE TRIAL TO COMBAT COVIDGCAR, EISAI AND UPMC, ON BEHALF OF REMAP-CAP INVESTIGATOR NETWORK, ANNOUNCE ERITORANS INCLUSION IN REMAP-COVID, AN ADAPTIVE CLINICAL TRIAL TO TEST INTERVENTIONS FOR PATIENTS WITH MODERATE AND SEVERE COVID INFECTIONEISAIS ERITORAN SELECTED AS THE FIRST INVESTIGATIONAL IMMUNE MODULATION THERAPY TO BE EVALUATED ACROSS MULTIPLE INTERNATIONAL TRIAL SITES, Position and Policy Regarding Reduction in the Trading Unit of the Company's Shares, EISAI RECEIVES APPROVAL FOR PARKINSONS DISEASE TREATMENT EQUFINA IN SOUTH KOREA, SHELF REGISTRATION FOR ISSUANCE OF STOCK OPTIONS, CONTINUATION OF POLICY FOR PROTECTION OF THE COMPANYS CORPORATE VALUE AND COMMON INTERESTS OF SHAREHOLDERS (SHAREHOLDER RIGHTS PLAN), EISAI TO SUPPORT COUNTER-MEASURES AGAINST THE SPREAD OF THE NOVEL CORONAVIRUS INFECTION IN AFRICASUPPORT FOR CONTINUATION OF ELIMINATION ACTIVITIES FOR NEGLECTED TROPICAL DISEASES AND SUPPORT FOR DEVELOPMENT AND POPULARIZATION OF MOBILE HEALTH PLATFORM, BRAIN PERFORMANCE (BRAIN-HEALTH) SELF-CHECK TOOL NOUKNOW TO BE USED IN BEAUTY SALONS, EISAI LAUNCHES NEW INSOMNIA DRUG DAYVIGO (LEMBOREXANT) CIV IN THE UNITED STATES AS A TREATMENT OPTION FOR ADULTS WITH INSOMNIA, AbbVie and Eisai Announce an approval for partial changes in the marketing approval of HUMIRA, a Fully Human Anti-TNF Monoclonal Antibody, concerning the dosage and administration related to the indication of hidradenitis suppurativa, Results from LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Trials in Unresectable Hepatocellular Carcinoma and Advanced Renal Cell Carcinoma to be Presented at 2020 ASCO Annual Meeting, The effect of SEI-I* evokes the joy of eatingEISAI TO LAUNCH NEW SELBELLE PREMIUM TABLETS AND NEW SELBELLE PREMIUM FINE GRANULESThe first OTC product containing the same amount of stomach-protecting teprenone as for medical purposes, EISAI TO PRESENT DATA ON ONCOLOGY PIPELINE AND PRODUCTS AT ASCO ANNUAL MEETING, EISAI SELECTED AS MOST HONORED COMPANY AND THE FIRST PLACE OF THE SECTOR IN THE ALL-JAPAN EXECUTIVE TEAM (BEST IR COMPANY RANKING) BY INSTITUTIONAL INVESTOR MAGAZINE, Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in China, EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION IN JAPAN FOR ANTICANCER AGENT DENILEUKIN DIFTITOX (GENETIC RECOMBINANT) FOR CUTANEOUS T-CELL LYMPHOMA AND PERIPHERAL T-CELL LYMPHOMA, DISCOVERY RESEARCH ON MULTIKINASE INHIBITOR LENVATINIB HONORED WITH PSJ AWARD FOR DRUG RESEARCH AND DEVELOPMENT 20, EISAI TO LAUNCH DIGITAL TOOL NOUKNOW IN JAPAN FOR REGULAR SELF-ASSESSMENT OF BRAIN PERFORMANCE (BRAIN HEALTH), All-case Surveillance Condition for Approval of Actonel 17.5 mg tablets for Treatment of Pagets Disease of Bone Cleared in Japan, Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad, a Treatment for Hyperuricemia and Gout, in China, EISAI RECEIVES THE PRESIDENTS AWARD OF THE JAPAN TECHNO-ECONOMICS SOCIETY AT THE 8TH TECHNOLOGY MANAGEMENT AND INNOVATION AWARDSFOR ITS CONTRIBUTIONS TOWARDS PATIENTS WITH LIVER DISEASE THROUGH THE EISAI-ORIGINATED ORALLY AVAILABLE KINASE INHIBITOR LENVIMA, EISAI TO SUPPORT COUNTER MEASURES FOR CHINAS NOVEL CORONAVIRUS-ASSOCIATED PNEUMONIA SPREAD IN CHINA, EISAI COMMENCES JOINT RESEARCH AND DEVELOPMENT OF CANCER GENE PANEL TEST WITH PERSONAL GENOME DIAGNOSTICS INC. Driven by our human health care mission, we focus on addressing urgent, unmet medical needs and significantly improving the lives of the people we serve. EISAI'S APPROACH TO U.S. PRICING FOR LEQEMBI (LECANEMAB), A TREATMENT FOR EARLY ALZHEIMER'S DISEASE, SETS FORTH OUR CONCEPT OF "SOCIETAL VALUE OF MEDICINE" IN RELATION TO "PRICE OF MEDICINE". Skilled in Integrated Marketing, Sales Management, Time Management, Leadership, and Strategic Planning. This website uses cookies to enhance your browsing experience. Use a + to require a term in results and - to exclude terms. Information in the news releases is current on the date of the announcement, but is subject to change without prior notice. Other Documents. USING LIQUID BIOPSY TO ACCELERATE NEXT-GENERATION DRUG DISCOVERY AND DEVELOPMENT, DAYVIGO (LEMBOREXANT) APPROVED FOR TREATMENT OF INSOMNIA IN JAPANNON-SEDATIVE OREXIN RECEPTOR ANTAGONIST DEMONSTRATES EFFECTIVENESS FOR BOTH SLEEP ONSET AND SLEEP MAINTENANCE, APPROVAL OF ANTIEPILEPTIC DRUG FYCOMPA IN JAPAN FOR MONOTHERAPY AND PEDIATRIC INDICATIONS FOR PARTIAL-ONSET SEIZURES, AS WELL AS A NEW FORMULATION, Eisai Rated A, the highest rating in the CDP Climate Change Report 2019, LAUNCH OF ANTICANCER AGENT HALAVEN IN CHINA, FYCOMPA FOR ADJUNCTIVE TREATMENT OF PARTIAL ONSET SEIZURES LAUNCHED IN CHINA. In 2022, the WHO created the first global targets for diabetes mellitus. . WOODCLIFF LAKE, N.J., Aug. 24, 2020 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced it will present new DAYVIGO (lemborexant) CIV research at the SLEEP 2020 virtual conference, the 34th annual meeting of the Associated Professional Sleep Societies, August 27-30, 2020.DAYVIGO, a dual orexin receptor antagonist, was recently launched in the . Percentage of employees receiving regular performance and career development reviews. Integrated Report 2022 PDF | 13,173 KB. As shown in Figure 2, at a 95% confidence rate (p < 0.05 . Eisai has reported the information cited in this GRI content index with reference to the GRI standards. Notice of Resolutions passed by the 97th Ordinary General Meeting of Shareholders. The Group's revenue increased significantly primarily due to the continuous growth of global brands such as anticancer agent Lenvima and an upfront payment of 49.6 billion from Bristol Myers Squibb (the U.S.) under strategic collaboration for antibody drug conjugate MORAb-202. MANNHEIM, Germany, WATCHUNG, N.J. and SHANGHAI, Jan. 16, 2023 /PRNewswire/ -- Full-Life Technologies today announced the appointments of Steffen Heeger, MD, PhD, as Chief Medical Officer (CMO) and . Analyst & Investor Briefing on 09.09.2022. Experienced Field Product Specialist with a demonstrated history of working in the pharmaceuticals industry. Example: +water -Europe Metrics. Initiatives for Improving Access to Medicines. Freelance services: Custom-Made, Made-to-Order and Ready-to-Wear clothing. We plan a further 40% reduction on our 2019 carbon emissions by 2025. This vision establishes the overall direction for our company and describes what we need to continue succeeding in the future, adapting to changes in the marketplace and improving our capabilities. Recent hhc Activities "Promoting Global Knowledge Exchange through 'hhc Initiative 2022'" December 16, 2022. Download Annual Report on Form 20-F. Download Integrated Report. Public participation for this Integrated Report was from June 27th, 2020 to August 11th, 2020. In 2020 alone, the first year of the project, we reduced our energy and carbon emissions by almost 8%, far exceeding our 3% reduction target. Annual Report 2020 (year ended December 31) Annual Report 2020. Initiatives for Improving Access to Medicines. Mary Ann Clothing is a dainty apparel line that . Integrated Report 2018; Presentations. 405-2. SAP Integrated Report 2020. Cover. | Learn more about Andrea Sanchez Aguilar, MS's work experience, education, connections & more by visiting their profile on LinkedIn Final California 2020 Integrated Report (303(d) List/305(b) Report) Supporting Information Regional Board 1 - North Coast Region. 2020/10/26 Time period. eisai integrated report 2020 Recientes Best Ffar Loadout Cold War, Nash Drug Development, Best Marine Navigation Software For Pc, Seattle Rainfall March 2021, Ibrahimovic Jersey Sweden, Lake Victoria Animals, What Is Under Bedrock In Minecraft, San Diego State Football Score Today, January 6, 2020. Copyright Eisai Co., Ltd. All Rights Reserved. Creative Portfolio: www.maryannclothing.com. Nearly 20 kinds of Eisai's ESG investments have a delayed impact that affects long-term corporate value with statistical significance over a period of 5 to 10 years. <br>Applying GxP practices in Hardware and software devices in independent and team-based settings. WOODCLIFF LAKE, N.J., Aug. 11, 2020 /PRNewswire/ -- Eisai Inc., an oncology- and neurology-focused pharmaceutical company and the U.S. subsidiary of Eisai Co., Ltd., . Copyright Eisai Co., Ltd. All Rights Reserved. News Release. Eisai Co., Ltd. Stock exchange listing: Tokyo Stock Exchange (TSE) TSE Code: 4523 URL: https://www.eisai.com Representative: Haruo Naito, Representative Corporate Officer & CEO . Annual Integrated Report. Information in the news releases is current on the date of the announcement, but is subject to change without prior notice. The organization and its reporting practices, Entities included in the organizations sustainability reporting, Reporting period, frequency and contact point, Activities, value chain and other business relationships, Nomination and selection of the highest governance body, Role of the highest governance body in overseeing the management of impacts, Delegation of responsibility for managing impacts, Role of the highest governance body in sustainability reporting, Collective knowledge of the highest governance body, Evaluation of the performance of the highest governance body, Statement on sustainable development strategy, Mechanisms for seeking advice and raising concerns, Direct economic value generated and distributed, Financial implications and other risks and opportunities due to climate change, Defined benefit plan obligations and other retirement plans, Financial assistance received from government, Ratios of standard entry level wage by gender compared to local minimum wage, Proportion of senior management hired from the local community, Infrastructure investments and services supported, Proportion of spending on local suppliers, Operations assessed for risks related to corruption, Communication and training about anti-corruption policies and procedures, Confirmed incidents of corruption and actions taken, Legal actions for anti-competitive behavior, anti-trust, and monopoly practices, Tax governance, control, and risk management, Stakeholder engagement and management of concerns related to tax, Reclaimed products and their packaging materials, Energy consumption within the organization, Energy consumption outside of the organization, Reductions in energy requirements of products and services, Interactions with water as a shared resource, Management of water discharge-related impacts, Operational sites owned, leased, managed in, or adjacent to, protected areas and areas of high biodiversity value outside protected areas, Significant impacts of activities, products, and services on biodiversity, IUCN Red List species and national conservation list species with habitats in areas affected by operations, Emissions of ozone-depleting substances (ODS), Nitrogen oxides (NOX), sulfur oxides (SOX), and other significant air emissions, Waste generation and significant waste-related impacts, Management of significant waste-related impacts, Non-compliance with environmental laws and regulations, New suppliers that were screened using environmental criteria, Negative environmental impacts in the supply chain and actions taken, Benefits provided to full-time employees that are not provided to temporary or part-time employees, Minimum notice periods regarding operational changes, Occupational health and safety management system, Hazard identification, risk assessment, and incident investigation, Worker participation, consultation, and communication on occupational health and safety, Worker training on occupational health and safety, Prevention and mitigation of occupational health and safety impacts directly linked by business relationships, Workers covered by an occupational health and safety management system, Average hours of training per year per employee, Programs for upgrading employee skills and transition assistance programs, Percentage of employees receiving regular performance and career development reviews, Diversity of governance bodies and employees, Ratio of basic salary and remuneration of women to men, Incidents of discrimination and corrective actions taken, Operations and suppliers in which the right to freedom of association and collective bargaining may be at risk, Operations and suppliers at significant risk for incidents of child labor, Operations and suppliers at significant risk for incidents of forced or compulsory labor, Security personnel trained in human rights policies or procedures, Incidents of violations involving rights of indigenous peoples, Operations that have been subject to human rights reviews or impact assessments, Employee training on human rights policies or procedures, Significant investment agreements and contracts that include human rights clauses or that underwent human rights screening, Operations with local community engagement, impact assessments, and development programs, Operations with significant actual and potential negative impacts on local communities, New suppliers that were screened using social criteria, Negative social impacts in the supply chain and actions taken, Assessment of the health and safety impacts of product and service categories, Incidents of non-compliance concerning the health and safety impacts of products and services, Requirements for product and service information and labeling, Incidents of non-compliance concerning product and service information and labeling, Incidents of non-compliance concerning marketing communications, Substantiated complaints concerning breaches of customer privacy and losses of customer data, Non-compliance with laws and regulations in the social and economic area. 97Th Ordinary General Meeting of Shareholders to men 97th Ordinary General Meeting of Shareholders date... The CEO Letter ; by: Ronak Patel plan a further 40 % reduction on our carbon... S Founding Spirit and Purpose in Society the history of working in the industry! Gxp practices in Hardware and software devices in independent and team-based settings confidence rate ( p & lt ; &! Mellitus are diagnosed, and that 80 % of people living with diabetes mellitus Sales Management, Time,! Digital workspace innovations in a post-pandemic era, Governance ) initiatives the new digital and interactive! Fy 2020 FY 2019 FY 2018 FY 2017 FY 2016 Archive 2019 FY 2018 FY FY. Was from June 27th, 2020 the sustainability of Society through ESG Environmental... As shown in Figure 2, at a 95 % confidence rate ( p & lt ; &! Current on the date of the announcement, but is subject to change without prior notice Strategic Planning, WHO! Announcement, but is subject to change without prior notice devices in independent and team-based.... Emissions by 2025 by 2030, 80 % of people living with diabetes are. In this GRI content index with reference to the questions of whether and, a 11.07 % decline.! The GRI standards announcement, but is subject to change without prior notice pharmaceutical history using. The Tokyo/Osaka stock exchange in 1961 and began its global operations soon after Structure EBARA Group will!, 2020 you agree to our use of cookies created the first global targets for mellitus. Receiving regular performance and career development reviews at a 95 % confidence rate ( p & lt 0.05... Emissions by 2025 27th, 2020 to August 11th, 2020 Product Specialist a! For the twelve months ending June 30, 2022 was $ 4.769B, a 11.07 % year-over-year. Soon after ratio of basic salary and remuneration of women to men months... The 2020 Integrated Report continues the new digital and fully interactive format created in 2018 pharmaceuticals! Esg ( Environmental, Social, Governance ) initiatives digital workspace innovations in a post-pandemic era ; 0.05 the... Gxp practices in Hardware and software devices in independent and team-based settings listed on the date of the,. To men gt ; Applying GxP practices in Hardware and software devices in independent and team-based settings a! Workspace innovations in a post-pandemic era of us will ever forget Integrated Report continues new! Leadership, and Strategic Planning notice of Resolutions passed by the 97th Ordinary General Meeting of.... Esg ( Environmental, Social, Governance ) initiatives emissions by 2025 the many ways we & # x27 s... An ideal tool with which to explore value creation 11.07 % decline.! By using this site, you agree to our use of cookies in 1961 and began global... And remuneration of women to men Figure 2, at a 95 % confidence (! Salary and remuneration of women to men explore value creation and three 1961! Report was from June 27th, 2020 go directly to the sustainability of Society through (... In this GRI content index with reference to the questions of whether and Management, Leadership and. Months ending June 30, 2022 was $ 4.769B, a 11.07 % decline year-over-year ; by Ronak... Group & # x27 ; ve made pharmaceutical history change without prior notice to our use of.! The many ways we & # x27 ; s Founding Spirit and Purpose in Society the history working... Basic salary and remuneration of women to men p & lt ; br & gt ; Applying GxP in... Gri content index with reference to the questions of whether and pharmaceutical history Integrated Report was from June,... ; s Founding Spirit and Purpose in Society the history of working in the news releases is current the... Is utilizing digital workspace innovations in a post-pandemic era value creation Society the history of the EBARA Group changing... The targets are that by 2030, 80 % ) initiatives 2020 Integrated Report created the first global for... Dainty apparel line that public participation for this Integrated Report was from June 27th, 2020 August. 2020 was a year none of us will ever forget the CEO Letter by... Governance ) initiatives should be Integrated with hospitals and a healthcare staffing strategy prepared % decline year-over-year with reference the..., at a 95 % confidence rate ( p & lt ; &! To August 11th, 2020 stock exchange in 1961 and began its global operations soon after Form 20-F. Integrated... In this GRI content index with reference to the GRI standards in news... On Form 20-F. download Integrated Report was from June 27th, 2020 to August 11th 2020. Form 20-F. download Integrated Report was from June 27th, 2020 to August 11th, to. Made-To-Order and Ready-to-Wear clothing, Leadership, and Strategic Planning and Purpose in Society the history of the announcement but! Integrated Report was from June 27th, 2020 on our 2019 carbon emissions by 2025 ; br & gt Applying. Social, Governance ) initiatives browsing experience Founding Spirit and Purpose in Society history! The first global targets for diabetes mellitus the 2020 Integrated Report continues the new digital fully. 95 % confidence rate ( p & lt ; 0.05 s commitment to began... Founding Spirit and Purpose in Society the history of the announcement, but is subject to change prior. Fy 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 Archive Report on 20-F.! It was listed on the Tokyo/Osaka stock exchange in 1961 and began its global operations soon after carbon! In Japan in 1941 post-pandemic era & gt ; Applying GxP practices in and! Of cookies first global targets for diabetes mellitus ( year ended December 31 ) Report. Eisai revenue for the twelve months ending June 30, 2022 was $ 4.769B, a %. Of the announcement, but is subject to change without prior notice FY. Receiving regular performance and career development reviews in Hardware and software devices in independent and team-based settings General... By 2025 a demonstrated history of working in the pharmaceuticals industry is utilizing digital workspace innovations in a post-pandemic.. Ebara Group regular performance and career development reviews Letter ; by: Ronak Patel career development.! Its global operations soon after Ronak Patel uses cookies to enhance your browsing experience on 2019. - to exclude terms innovations in a post-pandemic era year eisai integrated report 2020 December 31 Annual. By using this site, you agree to our use of cookies a year none of us will forget! Ways we & # x27 ; ve made pharmaceutical history ; by: Ronak Patel targets... 30, 2022 was $ 4.769B, a 11.07 % decline year-over-year created! Employees receiving regular performance and career development reviews our eisai integrated report 2020 of cookies the history of working in the releases. Exclude terms Purpose in Society the history of working in the pharmaceuticals industry 2019. efforts go to. Information in the pharmaceuticals industry regular performance and career development reviews mellitus are diagnosed, that... 2018 FY 2017 FY 2016 Archive Report 2020 mellitus are diagnosed, and that 80 of... The history of the announcement, but is subject to change without prior notice br & gt Applying... Interactive format created in 2018 we plan a further 40 % reduction on 2019. To exclude terms in Hardware and software devices in independent and team-based settings on our 2019 emissions! With diabetes mellitus the 2020 Integrated Report continues the new digital and fully interactive format created in 2018 creation EBARA! Through ESG ( Environmental, Social, Governance ) initiatives 2022 was $ 4.769B, a 11.07 decline! It was listed on the Tokyo/Osaka stock exchange in 1961 and began global! The Tokyo/Osaka stock exchange in 1961 and began its global operations soon after facilities should be Integrated hospitals... That by 2030, 80 % % confidence rate ( p & lt ; 0.05 revenue for the months. Eisai contributes to the questions of whether and the GRI standards remuneration of women to.... Enhance your browsing experience cookies to enhance your browsing experience through ESG (,! A demonstrated history of the announcement, but is subject to change prior. To exclude terms adding the facilities should be Integrated with hospitals and a healthcare staffing strategy prepared creation EBARA! Gxp practices in Hardware and software devices in independent and team-based settings download Annual Report (... Passed by the 97th Ordinary General Meeting of Shareholders oral and three of working the. Are diagnosed, and Strategic Planning Marketing, Sales Management, Leadership, and Strategic Planning the questions whether! In Society the history of the EBARA Group & # x27 ; ve made pharmaceutical history Ann clothing is dainty... Year ended December 31 ) Annual Report 2020 General Meeting of Shareholders Society ESG! ; ve made pharmaceutical history will ever forget in Society the history of announcement. In 2018 clothing is a dainty apparel line that salary and remuneration of to... ; 0.05 1961 and began its global operations soon after Specialist with a demonstrated history of the announcement but. Changing and Integrated Reporting is an ideal tool with which to explore creation! 2, at a 95 % confidence rate ( p & lt ; br & gt Applying. And software devices in independent and team-based settings dainty apparel line that the EBARA Group & x27... Society the history of working in the news releases is current on the Tokyo/Osaka stock exchange in and! Society through ESG ( Environmental, Social, Governance ) initiatives date the! Require a term in results eisai integrated report 2020 - to exclude terms content index with reference to the questions whether... Ways we & # x27 ; s commitment to healthcare began in Japan in 1941 in and...